Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Becomes the 7th International Registrational Clinical Trial for Ivonescimab Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 HONG KONG, Oct. 21, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that...